Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

BACKGROUND: Certolizumab pegol (CZP) is an Fc‐free, PEGylated anti‐tumour necrosis factor biologic. OBJECTIVES: To report the 3‐year efficacy of CZP in plaque psoriasis, pooled from the CIMPASI‐1 (NCT02326298) and CIMPASI‐2 (NCT02326272) phase III trials. METHODS: Adults with moderate‐to‐severe psor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, K.B., Warren, R.B., Gottlieb, A.B., Blauvelt, A., Thaçi, D., Leonardi, C., Poulin, Y., Boehnlein, M., Brock, F., Ecoffet, C., Reich, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247431/
https://www.ncbi.nlm.nih.gov/pubmed/32652544
http://dx.doi.org/10.1111/bjd.19393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247431/
https://www.ncbi.nlm.nih.gov/pubmed/32652544
http://dx.doi.org/10.1111/bjd.19393

Ejemplares similares